



# Synthesis and Biological Evaluation of 4 $\beta$ -N-Acetylamino Substituted Podophyllotoxin Derivatives as Novel Anticancer Agents

Jinbao Wei<sup>1,2</sup>, Jinghong Chen<sup>3</sup>, Peijun Ju<sup>3</sup>, Le Ma<sup>1</sup>, Li Chen<sup>2</sup>, Weidong Ma<sup>2</sup>, Tao Zheng<sup>2</sup>, Guangyi Yang<sup>4\*</sup> and Yong-Xiang Wang<sup>1\*</sup>

<sup>1</sup> King's Lab, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China, <sup>2</sup> Department of Pharmacy, Institute of Wudang Herbal Medicine Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China, <sup>3</sup> Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, <sup>4</sup> Baoan Hospital of Traditional Chinese Medicine, Shenzhen, China

## OPEN ACCESS

### Edited by:

Laurent G. Désaubry,  
Laboratoire de Cardio-Oncologie et  
Chimie Médicinale, Centre National de  
la Recherche Scientifique  
(CNRS), France

### Reviewed by:

Alexandra Paulo,  
Universidade de Lisboa, Portugal  
Shi-Wu Chen,  
Lanzhou University, China

### \*Correspondence:

Guangyi Yang  
ygy996@163.com  
Yong-Xiang Wang  
yxwang@sjtu.edu.cn

### Specialty section:

This article was submitted to  
Medicinal and Pharmaceutical  
Chemistry,  
a section of the journal  
Frontiers in Chemistry

Received: 14 December 2018

Accepted: 29 March 2019

Published: 24 April 2019

### Citation:


Wei J, Chen J, Ju P, Ma L, Chen L,  
Ma W, Zheng T, Yang G and Wang Y-X  
(2019) Synthesis and Biological  
Evaluation of 4 $\beta$ -N-Acetylamino  
Substituted Podophyllotoxin  
Derivatives as Novel Anticancer  
Agents. *Front. Chem.* 7:253.  
doi: 10.3389/fchem.2019.00253

A series of novel podophyllotoxin derivatives obtained by 4 $\beta$ -N-acetylamino substitution at C-4 position was designed, synthesized, and evaluated for *in vitro* cytotoxicity against four human cancer cell lines (EC-9706, HeLA, T-24 and H460) and a normal human epidermal cell line (HaCaT). The cytotoxicity test indicated that most of the derivatives displayed potent anticancer activities. In particular, compound **12h** showed high activity with IC<sub>50</sub> values ranging from 1.2 to 22.8  $\mu$ M, with much better cytotoxic activity than the control drug etoposide (IC<sub>50</sub>: 8.4 to 78.2  $\mu$ M). Compound **12j** exhibited a promising cytotoxicity and selectivity profile against T24 and HaCaT cell lines with IC<sub>50</sub> values of 2.7 and 49.1  $\mu$ M, respectively. Compound **12g** displayed potent cytotoxicity against HeLA and T24 cells with low activity against HaCaT cells. According to the results of fluorescence-activated cell sorting (FACS) analysis, **12g** induced cell cycle arrest in the G2/M phase accompanied by apoptosis in T24 and HeLA cells. Furthermore, the docking studies showed possible interactions between human DNA topoisomerase II $\alpha$  and **12g**. These results suggest that **12g** merits further optimization and development as a new podophyllotoxin-derived lead compound.

**Keywords:** podophyllotoxin derivatives, C-4 substitutions, anticancer agent, biological evaluation, structure–activity relationships (SAR)

## INTRODUCTION

Currently, cancer has become one of the most serious threats to public health across the globe, and it is considered the leading cause of death in developed countries and the second leading cause of death in developing countries (Jemal, 2011). Natural products have been an effective and successful method to identify novel hits and leads for curing this deadly disease (Cragg and Newman, 2013; Newman and Cragg, 2016). Podophyllotoxin (PPT, **1**), a natural product extracted from the plants of the *Podophyllum* family, exhibited significant anti-tumor and anti-viral activities, attracting great interest as a hallmark molecule because of its biological activities (MacRae et al., 1989; Lear and Durst, 1996; Gordaliza et al., 2004; Nandagopal and Routh, 2017). It has been stated that PPT exerted antitumor activity via inhibiting microtubule bundle formation in mitosis



metaphase, preventing the formation of the spindle and arresting cell division in metaphase (G2/M stage) (Damayanthi and Lown, 1998; Ravelli et al., 2004; Hartley et al., 2012).

Its excellent activity attracted much attention from scientists; however, PPT exerted serious side effects during cancer chemotherapy and had some therapeutic limitations, including high toxicity, poor water solubility, drug resistance and other unfavorable profiles (Damayanthi and Lown, 1998; Canel et al., 2000; Gordaliza et al., 2000). PPT was mainly used to cure dermatosis in clinical practice (Komericki et al., 2011; Lopez-Lopez et al., 2015). Hence, there is a need to develop safe and efficacious PPT derivatives for anticancer therapy to overcome the shortcomings. Aiming to find novel PPT derivatives with high efficiency and low toxicity, researchers carried out a series of structural modifications with podophyllin ingredients and obtained three potent semisynthetic glucoconjugates based on 4'-demethylpodophyllotoxin (DPPT; **2**), including etoposide (**3**), teniposide (**4**), and a water-soluble prodrug of etoposide, named etopophos (etoposide phosphate, **5**) (Figure 1) (Keller-Juslen et al., 1971; Greco and Hainsworth, 1996; Damayanthi and Lown, 1998; Hande, 1998). The semisynthetic glucoconjugates displayed favorable water solubility and are currently in clinical use for the treatment of various malignancies, including small cell lung cancer, testicular carcinoma, lymphoma, non-lymphocytic leukemia, and multiform glioblastoma (Issell, 1982; Loike, 1982; Witterland et al., 1996; Liu et al., 2015; Moon et al., 2017).


Although the solubility problem had been resolved, toxicity issues remain a challenge for the semisynthetic glucoconjugates. Furthermore, some non-sugar substituted PPT derivatives were developed, e.g., NK-611 (**6**), GL-331 (**7**), NPF (**8**), TOP-5 (**9**), and QS-ZYX-1-61 (**10**), which displayed a better pharmacology profile, exhibited excellent anti-tumor activity and reached clinical trials for the treatment of a broad spectrum of tumors (Utsugi et al., 1996; Shimizu et al., 2002; You, 2005; Lv and Xu, 2011; Kamal et al., 2015; Liu et al., 2015). These novel derivatives were obtained by modifying at the C-4 position of PPT/DPPT. Unlike **1**, the newly developed derivatives exerted high anti-tumor activity by inhibiting DNA topoisomerase II (Damayanthi and Lown, 1998; Gordaliza et al., 2000; Wilstermann et al., 2007; Kamal et al., 2015). Thus, the structural optimization of

PPT/DPPT is a desirable way to develop inhibitors of DNA topoisomerase II as new anticancer drugs (Srivastava et al., 2005; Khazir et al., 2014).


According to the previous structure-activity relationship (SAR) between PPT/DPPT and the clinical drug candidates, it has been proved that the tetralin nucleus structure of PPT/DPPT is important to keep the anti-tumor activity, which should remain unchanged; the dioxolane ring was essential. Additionally, the 4'-OCH<sub>3</sub> moiety was generally not essential, removal of it or introduction of the appropriate moiety at the C-4' position was acceptable. The C-4 position was one of the most important locations for structural optimization, and 4 $\beta$ -configuration was optimal and 4 $\beta$ -anilino substituted podophyllotoxin derivatives, including GL-331 (**7**), NPF (**8**), and QS-ZYX-1-61 (**10**), all of which were epipodophyllotoxin derivatives (4 $\beta$ -podophyllotoxin derivatives), showed potent cytotoxic activity against some human parental and drug-resistant cancer cell lines. The side chain structure, containing one or more basic center (amino group) at the C-4 position of PPT/DPPT, not only kept efficient anti-tumor activity but also reduced toxicity. In addition, the amino group easily turned into salt to improve the water solubility of the PPT/DPPT-derived derivatives (Zhang et al., 2010; Hyder et al., 2015; Kamal et al., 2015; Liu et al., 2015; Yu et al., 2017). GL-331 (**7**), NPF (**8**), TOP-53 (**9**), and QS-ZYX-1-61 (**10**), bearing a hydrophobic side-chain structure at C-4, exerted modest toxicity and potent anticancer activity. Hence, modification of semisynthetic non-glucoconjugates containing the hydrophobic side chain structure at C-4 is another feasible way to optimize the structure of PPT.

Based on the above analysis and the structures of newly developed clinical candidates **9-10** (Figure 2), we thought modification of non-glucoconjugates was another clue for designing new PPT derivatives. Taking into consideration the limitations of PPT derivatives, the target compounds was aimed at increasing the interactions with the target human DNA topoisomerase II $\alpha$  and simultaneously to overcome the toxicity problems of PPT derivatives. We anticipated that introduction of the hydrophobic side-chain structure at C-4 might increase the interactions with the hydrophobic pocket in the active site of human DNA topoisomerase II. Moreover, we used an N-acetylamino at C4 of PPT as a linker in the side chain. With the amino-group, the designed derivatives were able to undergo a salt-formation process under suitable conditions, which could also improve the required water solubility of PPT drugs. Consequently, an introduction of a side chain containing a diamido group at the C-4 position of PPT/DPPT would be a feasible approach to develop new PPT/DPPT derivatives as anticancer agents.

This paper reported the design and synthesis of a series of PPT/DPPT-derived derivatives (seen in graphical abstract) with the C-4 position of PPT/DPPT coupling 4 $\beta$ -N-acetylamino side chains which contained different types of substituted aliphatic hydrocarbons or aromatic hydrocarbons (types of substituents: aliphatic chain/carbocyclic ring, donating/withdrawing electron groups, steric hindrance groups, and hydrophobic/hydrophilic groups). The cytotoxic activity of the derivatives was tested *in vitro* against four human cancer cell lines (EC-9706, HeLa, T-24,



**FIGURE 1** | Structures of PPT, DPPT, and related compounds.



**FIGURE 2** | Rational design of the target compounds.

and H460) and a normal human epidermal cell line (HaCaT). Additional biological studies were conducted to analyze how novel compounds of this class affect the cell cycle. Docking studies were performed to investigate the possible binding interactions between synthesized compounds and the human topoisomerase II $\alpha$  active site and predict the mechanism of action as novel anticancer agents.

## CHEMISTRY


The synthetic route to 4 $\beta$ -N-acetylamino substituted PPT and DPPT derivatives **12a-t** is illustrated in **Scheme 1**. The derivatives were prepared with PPT and DPPT as the raw materials. Key intermediates 4 $\beta$ -chloroamido PPT/DPPT (**11** and **11a**) were synthesized in excellent yields by reaction with chloroacetonitrile (ClCH<sub>2</sub>CN) with the presence of 60% w/w methanesulfonate/aluminum oxide (MsOH/Al<sub>2</sub>O<sub>3</sub>). Subsequently, the key intermediate **11** or **11a** was reacted with substituted amines in the presence of potassium carbonate

and potassium iodate to afford a series of 4 $\beta$ -N-acetylamino substituted PPT and DPPT derivatives with good yields (**12a-t**). All newly synthesized compounds were purified by column chromatography and their chemical structures were confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and ESI-MS data.

## BIOLOGICAL EVALUATION

### Cytotoxicity and SAR

Target compounds **12a-t** were evaluated for *in vitro* cytotoxicity against four human tumor cell lines, including H460 (non-small cell lung carcinoma), HeLA (human cervical carcinoma), EC9706 (human esophageal squamous cell carcinoma), and T24 (human bladder carcinoma), using HaCaT (human immortalized epidermal cells) as a human non-malignant cell line. Etoposide (**3**) was included as a positive control. The screening procedure was based on the 3-(4, 5-dimethylthiazol-2-yl)-5-diphenyltetrazolium bromide (MTT) growth inhibition assay with triplicate experiments, and the results are summarized in **Table 1**.



**SCHEME 1** | Synthesis of 4 $\beta$ -N-acetylamino substituted PPT and DPPT derivatives **12a-t**.

Notably, in comparison to the data of **Table 1**, it was clear that DPPT-derived derivatives showed better cytotoxic activity than the PPT-derived derivatives with C-4' OCH<sub>3</sub> substituent, suggesting that demethylation at C-4' of PPT could improve the cytotoxicity against tumor cell lines. Among the analogs derived from DPPT, compounds **12h** and **12s** showed superior activity (IC<sub>50</sub> 1.21–1.57 and 2.27–5.94  $\mu$ M, respectively) compared with etoposide (IC<sub>50</sub> 3.12–43.17  $\mu$ M) against HeLA and H460 tumor cell lines. Meanwhile, the two compounds also showed significant cytotoxicity against the HaCaT cell line with IC<sub>50</sub> values of 1.54 and 8.67  $\mu$ M, respectively.

Compounds **12d–e** containing a morpholine ring substituent at the C-2'' position of the acetylamino moiety lost their cytotoxicity against the cancer cell lines as well as the normal cell line with IC<sub>50</sub> values >50  $\mu$ M. Moreover, Compounds **12a–b** bearing a five or six-membered aliphatic ring displayed poor cytotoxicity, which showed comparable potency to compound **12n** with a phenyl group. When the 2''-substituent was changed from phenyl (**12n**) to p-hydroxyphenylethyl (**12s**), the cytotoxicity against HeLA improved with IC<sub>50</sub> values from 6.26 to 2.27  $\mu$ M. Compound **12k** with disubstituted ethyl group showed poor cytotoxicity, while compound with disubstituted n-propyl group (**12g**) showed more significant improved potency and selectivity of cytotoxicity against the cancer cell lines than the mono-substituted compound (**12f**), which was similar to that observed between **12h** and **12j**. The results suggested that an introduction of the hydrophobic disubstituted alkyl group might be important for the cytotoxicity and selectivity of antitumor effects. To assess the inhibitory effect of the active derivative (**12g**) on cancer cells, Hoechst 33258 staining and flow cytometry analysis on HeLA and T24 cells were conducted.

## Morphological Changes and Apoptosis

Apoptosis is one of the major pathways leading to the process of cell death. Visualization of chromatin condensation as well as nuclear shrinking and fragmentation—known as classic characteristics of apoptosis—was carried out in the presence of a representative compound **12g** by staining T24 and HeLA cells with Hoechst 33258, by which apoptosis was confirmed as the cause of reduced cell viability. As shown in **Figure 3**, treatment of **12g** at three different gradient concentrations markedly increased chromatin condensation, nuclear fragmentation and morphological changes as compared to the vehicle (0.1% DMSO)-treated cells, demonstrating that the cells undergo apoptosis (the arrowhead indicated an apoptotic nucleus), while negative control cells displayed excellent growth characteristics. Thus, these results evidently indicated that the compound **12g** is effective in inducing cellular apoptosis.

## Cell Cycle Analysis

Flow cytometry analysis was carried out to evaluate cell cycle changes and gain further insight into the mode of action with respect to the anti-proliferative effect of compound **12g**. HeLA and T24 cancer cells were treated with the selected compound **12g** for 48 h at three different gradient concentrations. The

**TABLE 1** | *In vitro* cytotoxicity of compounds **12a–t** against five human tumor cell lines with etoposide as control (IC<sub>50</sub>).

Compds.	IC <sub>50</sub> ( $\mu$ M) <sup>a</sup>				
	EC9706	HeLA	T24	H460	HaCaT
<b>12a</b>	>50	12.72 $\pm$ 1.38	>50	9.61 $\pm$ 0.22	18.16 $\pm$ 1.28
<b>12b</b>	>50	5.72 $\pm$ 0.74	>50	5.91 $\pm$ 0.65	5.17 $\pm$ 0.36
<b>12c</b>	>50	>50	>50	>50	1.89 $\pm$ 0.27
<b>12d</b>	>50	>50	>50	>50	>50
<b>12e</b>	>50	>50	>50	>50	>50
<b>12f</b>	11.65 $\pm$ 0.26	23.85 $\pm$ 1.04	18.63 $\pm$ 1.57	2.54 $\pm$ 0.34	2.59 $\pm$ 0.13
<b>12g</b>	>50	2.34 $\pm$ 0.39	2.98 $\pm$ 0.26	24.19 $\pm$ 0.77	>50
<b>12h</b>	22.78 $\pm$ 0.32	1.21 $\pm$ 0.31	12.10 $\pm$ 1.28	1.57 $\pm$ 0.37	1.54 $\pm$ 0.29
<b>12i</b>	>50	>50	>50	37.77 $\pm$ 1.01	>50
<b>12j</b>	35.56 $\pm$ 0.91	42.92 $\pm$ 0.69	2.68 $\pm$ 0.40	26.12 $\pm$ 0.98	49.08 $\pm$ 1.67
<b>12k</b>	>50	45.76 $\pm$ 0.71	>50	>50	>50
<b>12l</b>	>50	>50	>50	>50	4.21 $\pm$ 0.17
<b>12m</b>	>50	36.40 $\pm$ 0.49	>50	>50	>50
<b>12n</b>	40.13 $\pm$ 2.43	6.25 $\pm$ 0.21	>50	16.51 $\pm$ 0.39	13.30 $\pm$ 0.80
<b>12o</b>	11.34 $\pm$ 0.22	8.55 $\pm$ 0.28	>50	26.86 $\pm$ 0.92	2.14 $\pm$ 0.33
<b>12p</b>	>50	>50	>50	9.75 $\pm$ 0.26	>50
<b>12q</b>	20.68 $\pm$ 0.72	4.57 $\pm$ 0.30	>50	3.43 $\pm$ 0.17	3.69 $\pm$ 0.19
<b>12r</b>	>50	>50	>50	>50	>50
<b>12s</b>	14.32 $\pm$ 0.69	2.27 $\pm$ 0.26	12.7 $\pm$ 0.73	5.94 $\pm$ 0.18	8.67 $\pm$ 0.72
<b>12t</b>	>50	>50	>50	42.07 $\pm$ 1.21	>50
Etoposide	>50	3.12 $\pm$ 0.35	8.43 $\pm$ 0.33	43.17 $\pm$ 1.45	48.74 $\pm$ 1.69


Human tumor cells were treated with different concentrations of samples for 48 h ( $n = 3$  independent experiments).

<sup>a</sup>Data are presented as IC<sub>50</sub> ( $\mu$ M, the concentration of 50% proliferation inhibitory effect).


cell cycle accumulation was examined by the propidium iodide staining and cytometric quantification after the cancer cells were cultured for 24 h. As shown in **Figure 4**, in HeLA cells treated with **12g**, 79.69, 89.18, and 90.66%, respectively, of cells were in G2/M phase, compared to only 18.29% of control (untreated) cells in this phase. It was clear that the percentage of G2/M cells showed a remarkable increase in HeLA cells along with the increasing concentrations of **12g**. Additionally, treated compound **12g** with concentrations of 0.75, 1.5, and 3.0  $\mu$ M resulted in large accumulations of T24 cells at G2/M phase of 65.15, 62.76, and 79.87%, respectively. These results indicated that compound **12g** efficiently arrested the cancer cells at G2/M phase.

## DOCKING STUDY

Aiming to investigate the possible binding interactions of synthesized compound **12g** inside the human topoisomerase II $\alpha$  active site and to predict the mechanism of action as anti-cancer agent, a molecular docking study was performed using Autodock 4.0 as modeling software. An X-ray crystal structure of the human DNA topoisomerase II $\alpha$  active site in complex with its ligand AMP-PNP was downloaded from the protein data bank (PDB code: 1ZXM). As shown in **Figure 5A**, the three-dimensional structure of the 1ZXM crystal



**FIGURE 3** | Fluorescent images of Hoechst 33258 staining showing compound **12g** induced cell death with 0.1% DMSO vehicle as the control. Cells were examined under a fluorescence microscope. The arrows indicated the formation of apoptotic bodies with condensed chromatin or fragmented chromatin. **(A)** Treatment of T24 cells with **12g** for 24 h. **(B)** Treatment of HeLa cells with **12g** for 24 h. The apoptosis rates of T24 and HeLa cells with treatment of **12g** were quantify and analyzed by One-way ANOVA ( $n = 3$  in each treatment). \* $P < 0.05$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$  compared with the vehicle (0.1% DMSO). The statistical data are presented as mean  $\pm$  S.D. Scale bar = 50  $\mu$ m.



Cell lines	Cell cycle phase (%)			
	Conc. (uM)	G0/G1	S	G2/M
T24	Control (0)	30.91	51.83	17.26
	0.5 uM	5.58	29.27	65.15
	1 uM	1.16	36.08	62.76
	2 uM	0.63	19.49	79.87
HeLa	Control (0)	52.19	29.52	18.29
	0.75 uM	0.43	19.88	79.69
	1.5 uM	0.53	10.29	89.18
	3 uM	3.5	5.84	90.66

**FIGURE 4** | Compound **12g** affected the cancer cell cycle distribution at three different gradient concentrations with 0.1% DMSO vehicle as the control. **(A)** T24 cells treated with **12g** for 24 h. **(B)** HeLa cells treated with **12g** for 24 h.

is composed of 7  $\alpha$ -helixes, 13  $\beta$ -folds, and random coils, which subsequently forms a hydrophobic groove functioning as the active site or binding pocket (**Figures 5A,B**). The active site is located at the center of the enzyme, where small molecule compounds including podophyllotoxin derivatives occupy to block the entry of ligands into the binding site (**Figure 5C**).


In **Figure 6**, it represented the docking pose of **12g** in the binding pocket, where it is enclosed by ILE88, ASN91, ALA92, ASN95, ARG98, ASN120, ILE125, ILE141, PHE142, SER149, and ILE217 residues. Inhibitor **12g** was found to form 3 hydrogen bonding interactions with ASN91, ARG98 and ILE125 amino acid residues inside the DNA topoisomerase II $\alpha$  active site with distances of 2.9, 3.4, and 3.5  $\text{\AA}$ , respectively, and the following

binding energy: E-score =  $-10.46$  Kcal/mol. The aromatic ring at the C-1 position of DPPT was involved in  $\pi$ - $\pi$  stacking with the aromatic residue of PHE142. Additionally, hydrophobic interactions of dipropyl with ILE125 and ILE141 served to stabilize the side-chain structure of **12g**, accounting for its good antitumor activity in MTT testing. As shown in MTT testing, whereas compound **12i** with a butyl side chain was not more cytotoxic than **12g**, we thought that dibutyl side chain of **12i** was more flexible than n-propyl group of **12g**, which might weaken the hydrophobic interaction with human topoisomerase II hydrophobic pocket. In addition, a bigger group occupied a larger space in the receptor pocket, leading to the necessity for more hydrophobic amino acid residues to maintain conformation stability. As a result, bigger side chains would probably be positioned outside the active pocket.

In accordance with the data of MTT testing *in vitro*, docking results also showed that PPT derivative **12g**, which contained the hydrophobic side-chain structure, exerted relatively potent cytotoxicity on cancer cells compared with other analogs, which proved our expectations of the design. Hence, an introduction of hydrophobic side-chain structure with appropriate size at the C-4 position of DPPT may increase the biological activity via interaction with the hydrophobic groove of DNA topoisomerase II $\alpha$ . All these interactions enhanced the hydrophobic groove binding affinity of the 4 $\beta$ -N-acetylamino substituted podophyllotoxin derivatives.

## CONCLUSIONS

According to previous SAR studies on PPT/DPPT and their clinical drug candidates, a series of novel PPT/DPPT derivatives was designed and synthesized to increase the interactions with the target human DNA topoisomerase II $\alpha$  and simultaneously to improve the toxicity issues of DPPT derivatives. These derivatives were evaluated for anti-tumor activity *in vitro* against several human tumor cell lines using an MTT assay. Among the analogs, compounds **12h** and **12s** showed superior activity against HeLa and H460 tumor cell lines with IC<sub>50</sub> values of 1.21/1.57 and 2.27/5.94  $\mu$ M, respectively. Moreover, compound **12g** derived from DPPT was one of the most promising synthetic derivatives, with greater potency and selectivity of cytotoxicity than the positive control etoposide, and was selected as lead molecule for further development, inducing cell cycle arrest in the G2/M phase and apoptosis in both HeLa and T24 cells. The above preliminary investigation of cytotoxicity and SAR suggested that a substituted hydrophobic group at C-4 of PPT and free C-4' OH had a major impact on the cellular activity. An introduction of hydrophobic disubstituted alkyl group on the acetylamino moiety was advantageous. Removal of CH<sub>3</sub> at the C-4' position of PPT would increase water solubility, which contributed to enhancing bioavailability. Introducing polar groups that were hydrolyzable *in vivo* via enzymes or non-enzymes at the C-4' OH position of DPPT was a feasible way to achieve a DPPT prodrug like etoposide. The docking studies disclosed hydrophobic side-chain structure with appropriate size at the C-4 position of DPPT would enhance the hydrophobic interactions



with the hydrophobic amino acid residues within human DNA topoisomerase II $\alpha$ . In conclusion, due to **12g** and other derivatives' excellent anti-proliferative potency and remarkable apoptosis-inducing activity, further studies to substantiate and improve activity profiles are ongoing.

## EXPERIMENTAL SECTION


### Chemistry

All solvents, reagents, and chemicals for the synthesis of the compounds were of analytical grade, purchased from commercial sources and used without further purification, unless otherwise specified. Melting points were taken on a Kofler melting point apparatus and are uncorrected. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were measured on a Bruker Ascend™-400 spectrometer (Bruker Company, USA) with tetramethylsilane (TMS) as an internal standard. All chemical shift values are expressed in  $\delta$  parts per million. Mass spectra were recorded on a Waters-XEVO UPLC/MS/MS spectrometer with ESI source as ionization. Podophyllotoxin (PPT, **1**) and 4'-demethylpodophyllotoxin (DPPT, **2**) were isolated from the Chinese medicinal herb *Diosma versipellis* and served as the starting materials for the preparation of all new derivatives.

### Chemistry

#### General Synthetic Procedure for the Key Intermediates 4 $\beta$ -Chloroamido-Podophyllotoxin (**11**) and 4 $\beta$ -Chloroamido-4'-Demethylpodophyllotoxin (**11a**)

To a stirred mixture of PPT or DPPT (4 mmol) and ClCH<sub>2</sub>CN (10 mL), a homogeneous mixture of MsOH/Al<sub>2</sub>O<sub>3</sub> (60 mass %, 1 g) was added, and the mixture was irradiated by an ultrasonic generator in a water bath at 60°C for 30 min, then evaporated



**FIGURE 6** | Docking poses for compound **12g** in the active site of human DNA topoisomerase II $\alpha$ . **(A)** X-ray crystal structure of human DNA topoisomerase II $\alpha$  active site in complex with **12g** (green). **(B)** Inhibitor **12g** was bound to the hydrophobic groove of DNA topoisomerase II $\alpha$ . **(C,D)** View of compound **12g** (green) docked in the binding residues of human topoisomerase II $\alpha$  from different perspectives.

under reduced pressure (Li et al., 2013). The residue was purified by chromatography on silica gel using EtOAc–petroleum ether to give the key intermediate **11** or **11a**.

#### General Synthetic Procedure for Compounds **12a–t**

The key intermediate **11** or **11a** (1.0 mmol) was added to a solution of various substituted amines (1.2 mmol), potassium iodate (0.1 mmol) and potassium carbonate (2.4 mmol) in dry acetonitrile (10 mL). The reaction mixture was stirred for 2.5 h at 65°C, then evaporated under reduced pressure. The residue was purified by chromatography on silica gel using EtOAc–petroleum ether to give compounds **12a–t** (detailed steps and NMR data were available in **Supporting Information**).

#### 4 $\beta$ -N-[(2'-(pyrrolidine)-acetamide)-4'-demethylpodophyllotoxin (**12a**)

Yield 76% from **11** as a white solid; mp: 113–116 °C;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ ):  $\delta$  8.25 (d,  $J = 9.3$  Hz, 1H, CONH), 6.97 (s, 1H, H-5), 6.83 (s, 1H, H-8), 6.44 (s, 2H, H-2', 6'), 6.02 (2s, 2H, OCH<sub>2</sub>O), 5.14 (dd,  $J = 9.1, 6.2$  Hz, 1H, H-4), 4.39 (s, 1H, OH-4'), 4.28 (m, 1H, H-1), 4.11 (m, 1H, 11 $\beta$ -H), 3.80 (m, 1H, 11 $\alpha$ -H), 3.71 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.64 (m, 1H, H-2), 3.34 (m, 1H, H-3), 3.20 (d, 2H, COCH<sub>2</sub>), 2.55 (m, 4H, CH<sub>2</sub>NCH<sub>2</sub>), 1.71 (m, 4H, CH<sub>2</sub>CH<sub>2</sub>);  $^{13}\text{C}$  NMR (101 MHz, DMSO- $d_6$ ):  $\delta$  179.13, 172.60, 170.51, 148.35, 146.93, 146.80, 134.73, 131.67, 131.02, 129.61, 110.10, 106.09, 105.47, 101.48, 68.18, 58.86, 56.49, 54.09, 46.36, 45.63, 44.08, 37.70, 23.81, 21.61; ESI-MS:  $m/z$  511.5 [M+H] $^+$ .

#### 4 $\beta$ -N-[2'-(piperidine)-acetamide]-4'-demethylpodophyllotoxin (**12b**)

Yield 81% from **11** as a white solid; mp: 107–110 °C;  $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.30 (d,  $J = 8.6$  Hz, 1H, CONH), 8.02 (s, 1H, OH-4'), 6.80 (s, 1H, H-5), 6.65 (s, 1H, H-8), 6.38 (s, 2H, H-2', 6'), 5.98 and 5.96 (2s,  $J = 8.1$  Hz, 2H, OCH<sub>2</sub>O), 5.31 (s, 1H, H-4), 4.47 (d, 1H, H-1), 4.40–4.30 (m, 1H, 11 $\beta$ -H), 4.15 (m, 1H, 11 $\alpha$ -H), 3.83 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.47 (dd,  $J = 10.5, 2.9$  Hz, 1H, H-2), 3.35 (d, 2H, COCH<sub>2</sub>), 3.30 (m, 1H, H-3), 2.74 (t, 4H, CH<sub>2</sub>NCH<sub>2</sub>), 1.72 (m, 4H, CH<sub>2</sub>), 1.52 (m, 2H, CH<sub>2</sub>);  $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  178.61, 176.01, 168.97, 147.57, 147.40, 147.31, 133.73, 132.60, 130.59, 128.38, 110.10, 106.04, 104.55, 101.33, 68.45, 60.83, 56.44, 54.50, 47.79, 45.43, 45.32, 38.06, 25.06, 22.91, 21.24; ESI-MS:  $m/z$  525.5 [M+H] $^+$ , 563.6 [M+K] $^+$ .

#### 4 $\beta$ -N-[2'-(piperidine)-acetamide]-podophyllotoxin (**12c**)

Yield 87% from **11** as a white solid; mp: 229–231 °C;  $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.66 (d,  $J = 7.5$  Hz, 1H, CONH), 6.71 (s, 1H, H-5), 6.55 (s, 1H, H-8), 6.30 (s, 2H, H-2', 6'), 5.99 (s, 2H, OCH<sub>2</sub>O), 5.44 (s, 1H, H-1), 5.21 (dd,  $J = 7.5, 4.4$  Hz, 1H, H-4), 4.63 (d,  $J = 4.7$  Hz, 1H, 11 $\beta$ -H), 4.43 (m, 11 $\alpha$ -H), 3.81 (s, 3H, 4'-OCH<sub>3</sub>), 3.75 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.11 (d, 2H, COCH<sub>2</sub>), 3.04 (m, 1H, H-2), 2.92 (d, 1H, H-3), 2.55 (d, 4H, CH<sub>2</sub>NCH<sub>2</sub>), 1.67 – 1.51 (m, 4H, CH<sub>2</sub>CH<sub>2</sub>), 1.50 – 1.41 (m, 2H, CH<sub>2</sub>);  $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  174.40, 170.47, 152.62, 148.33, 147.66, 137.21, 134.82, 132.27, 129.03, 110.19, 108.69, 108.17, 101.62, 69.02, 61.67, 60.77, 56.22, 54.84, 47.69, 43.82, 41.81, 37.30, 25.77, 25.41, 23.29, 21.30; ESI-MS:  $m/z$  561.6 [M+Na] $^+$ .



**4 $\beta$ -N-[2'-(morpholino)-acetamide]-4'-demethylpodophyllotoxin (12d)**

Yield 82% from **11** as a white solid; mp: 109–111 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.33 (s, 1H, OH-4'), 8.26 (d, *J* = 8.2 Hz, 1H, CONH), 6.96 (s, 1H, H-5), 6.85 (s, 1H, H-8), 6.45 (s, 2H, H-2', 6'), 6.03 (s, 2H, OCH<sub>2</sub>O), 5.14 (s, 1H, H-4), 4.39 (s, 1H, H-1), 4.28 (m, 1H, 11 $\beta$ -H), 4.12 (m, 1H, 11 $\alpha$ -H), 3.81 (m, 1H, H-2), 3.71 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.61 (s, 4H, CH<sub>2</sub>OCH<sub>2</sub>), 3.45 (s, 1H, H-3), 3.37 (s, 4H, CH<sub>2</sub>NCH<sub>2</sub>), 3.10 (s, 2H, COCH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  179.11, 169.83, 148.36, 146.93, 146.84, 134.75, 131.73, 131.04, 129.52, 115.65, 115.44, 115.08, 115.00, 110.10, 106.16, 105.51, 101.50, 68.14, 66.54, 61.54, 56.50, 53.57, 46.41, 45.58, 44.03, 37.74, 19.03; ESI-MS: *m/z* 527.5 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2'-morpholino)-acetamide]-podophyllotoxin (12e)**

Yield 81% from **11** as a white solid; mp: 119–121 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.43 (d, *J* = 9.1 Hz, 1H, CONH), 6.73 (s, 1H, H-5), 6.55 (s, 1H, H-8), 6.39 (s, 2H, H-2', 6'), 5.97 and 5.96 (2s, 2H, OCH<sub>2</sub>O), 5.39 (dd, *J* = 9.1, 5.1 Hz, 1H, H-4), 4.37–4.31 (m, 2H, H-11), 3.84 (s, 3H, 4'-OCH<sub>3</sub>), 3.82 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.75 (s, 1H, H-1), 3.72 (t, 4H, morpholino-CH<sub>2</sub>OCH<sub>2</sub>-), 3.34 (dd, *J* = 10.0, 3.8 Hz, 1H, H-2), 3.23 (m, 1H, H-3), 3.06 (d, 2H, COCH<sub>2</sub>), 2.55 (m, 4H, morpholino-CH<sub>2</sub>NCH<sub>2</sub>-); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  178.33, 170.42, 153.59, 147.89, 147.25, 138.51, 137.01, 130.72, 128.43, 109.91, 106.75, 105.11, 101.41, 68.72, 67.05, 61.84, 60.88, 56.24, 53.90, 48.00, 45.08, 44.70, 38.26; ESI-MS: *m/z* 541.6 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[2'-(*n*-propylamine)-acetamide]-4'-demethylpodophyllotoxin (12f)**

Yield 81% from **11** as a white solid; mp: 199–202 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.99 (s, 1H, OH-4') 7.61 (d, *J* = 7.9 Hz, 1H, CONH), 6.73 (s, 1H, H-5), 6.53 (s, 1H, H-8), 6.30 (s, 2H, H-2', 6'), 5.98 and 5.97 (2s, 2H, OCH<sub>2</sub>O), 5.24 (dd, *J* = 7.9, 4.6 Hz, 1H, H-4), 4.59 (d, *J* = 4.8 Hz, 1H, H-1), 4.44–4.35 (m, 1H, 11 $\beta$ -H), 3.83 (m, 1H, 11 $\alpha$ -H), 3.76 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.71 (d, *J* = 7.0 Hz, 1H, H-2), 3.36 (d, 2H, COCH<sub>2</sub>), 2.96 (s, 1H, NH), 2.88 (m, 1H, H-3), 1.54–1.38 (m, 2H, CH<sub>2</sub>), 1.23 (t, *J* = 7.0 Hz, 2H, N-CH<sub>2</sub>-), 0.87 (t, *J* = 7.4 Hz, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  174.51, 171.84, 148.30, 147.57, 146.53, 134.08, 132.43, 130.29, 129.04, 110.12, 108.90, 107.83, 101.58, 69.00, 58.37, 56.40, 52.03, 47.54, 43.59, 41.88, 37.18, 22.89, 18.39, 11.52; ESI-MS: *m/z* 499.5 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2'-(dipropylamine)-acetamide)-4'-demethylpodophyllotoxin (12g)**

Yield 86% from **11** as a white solid; mp: 125–128 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.29 (s, 1H, CONH), 8.12 (s, 1H, OH-4'), 6.77 (s, 1H, H-5), 6.55 (s, 1H, H-8), 6.25 (s, 2H, H-2', 6'), 6.01 and 5.99 (2s, 2H, OCH<sub>2</sub>O), 5.19 (dd, *J* = 8.4, 4.8 Hz, 1H, H-4), 4.51 (d, *J* = 5.2 Hz, 1H, H-1), 4.31 (t, *J* = 8.0 Hz, 1H, 11 $\beta$ -H), 3.75 (m, 1H, 11 $\alpha$ -H), 3.64 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.37 (s, 2H, COCH<sub>2</sub>), 3.20 (dd, *J* = 14.5, 5.2 Hz, 1H, H-2), 3.03–2.92 (m, 1H, H-3), 2.53 (s, 4H, 2NCH<sub>2</sub>), 1.50–1.35 (m, 4H, 2CH<sub>2</sub>), 0.80 (t, *J* = 7.3 Hz, 6H); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  174.94, 172.50, 162.78, 147.70, 147.61, 147.05, 135.15, 132.83, 130.56, 130.48, 109.97,

109.32, 108.88, 101.73, 68.81, 56.59, 56.44, 47.16, 43.34, 41.32, 37.03, 36.25, 31.23, 21.53, 11.95; ESI-MS: *m/z* 541.6 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2'-(*n*-butylamine)-acetamide)-4'-demethylpodophyllotoxin (12h)**

Yield 83% from **11** as a white solid; mp: 115–118 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.28 (d, *J* = 8.3 Hz, 1H, CONH), 7.70 (m, 1H, OH-4'), 6.77 (s, 1H, H-5), 6.55 (s, 1H, H-8), 6.25 (s, 2H, H-2', 6'), 6.02 and 5.99 (2s, 1H, OCH<sub>2</sub>O), 5.21 (dd, *J* = 8.0, 4.7 Hz, 1H, H-4), 4.51 (d, *J* = 5.1 Hz, 1H, H-1), 4.29 (t, 1H, 11 $\beta$ -H), 3.78 (m, 1H, 11 $\alpha$ -H), 3.73 (s, 1H, NH), 3.64 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.26 (d, 2H, COCH<sub>2</sub>), 3.23–3.14 (m, 1H, H-2), 3.03–2.91 (m, 1H, H-3), 2.55 (m, 2H, NCH<sub>2</sub>), 1.44–1.34 (m, 2H, CH<sub>2</sub>), 1.32–0.23 (m, 2H, CH<sub>2</sub>), 0.86 (t, *J* = 7.3 Hz, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  174.95, 172.63, 170.82, 147.70, 147.60, 147.03, 135.13, 132.79, 130.60, 130.57, 109.92, 109.42, 108.86, 101.72, 56.42, 51.73, 48.78, 47.16, 43.35, 41.32, 37.02, 31.33, 21.68, 20.26, 14.27; ESI-MS: *m/z* 535.6 [M+Na]<sup>+</sup>.

**4 $\beta$ -N-[(2'-(*n*-butylamine)-acetamide)-podophyllotoxin (12i)**

Yield 82% from **11** as a white solid; mp: 92–95 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.42 (d, *J* = 8.2 Hz, 1H, CONH), 6.79 (s, 1H, H-5), 6.56 (s, 1H, H-8), 6.30 (s, 2H, H-2', 6'), 6.02 and 6.00 (2s, 2H, OCH<sub>2</sub>O), 5.23 (dd, *J* = 8.0, 4.6 Hz, 1H, H-4), 4.57 (d, *J* = 5.3 Hz, 1H, H-1), 4.31 (m, 1H, 11 $\beta$ -H), 3.88–3.77 (m, 1H, 11 $\alpha$ -H), 3.73 (s, 1H, NH), 3.66 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.62 (s, 3H, 4'-OCH<sub>3</sub>), 3.34 (s, 2H, COCH<sub>2</sub>), 3.25 (dd, *J* = 14.5, 5.4 Hz, 1H, H-2), 3.05–2.94 (m, 1H, H-3), 2.60 (t, *J* = 6.9 Hz, 2H, NCH<sub>2</sub>), 1.49–1.38 (m, 2H, CH<sub>2</sub>), 1.36–1.21 (m, 2H, CH<sub>2</sub>), 0.86 (t, *J* = 7.3 Hz, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  174.86, 172.55, 152.46, 147.78, 147.13, 136.79, 136.21, 132.40, 130.58, 109.91, 109.51, 108.56, 101.77, 60.35, 56.21, 51.15, 48.52, 47.18, 43.53, 41.16, 37.05, 30.77, 21.59, 20.18, 14.22; ESI-MS: *m/z* 527.6 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2'-(dipropylamine)-acetamide)-4'-demethylpodophyllotoxin (12j)**

Yield 78% from **11** as a white solid; mp: 70–72 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.03 (d, *J* = 9.3 Hz, 1H, CONH), 6.91 (s, 1H, H-5), 6.79 (s, 1H, OH-4'), 6.56 (s, 1H, H-8), 6.45 (s, 2H, H-2', 6'), 6.02 (s, 1H, OCH<sub>2</sub>O), 5.15 (dd, *J* = 8.9, 2.7 Hz, 1H, H-4), 4.35 (d, 1H, H-1), 4.09 (m, 1H, 11 $\beta$ -H), 3.80 (m, 1H, 11 $\alpha$ -H), 3.71 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.32 (m, 1H, H-3), 3.18 (dd, *J* = 14.1, 5.4 Hz, 1H, H-2), 3.10 (s, 2H, COCH<sub>2</sub>), 2.45 (m, 4H, CH<sub>2</sub>NCH<sub>2</sub>), 1.39 (m, 4H, 2CH<sub>2</sub>), 1.27 (m, 6H, 2CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  179.01, 171.44, 148.39, 147.61, 146.97, 146.94, 134.82, 131.77, 131.22, 129.58, 108.88, 105.59, 101.54, 57.89, 56.48, 56.43, 54.89, 54.53, 48.97, 45.48, 44.03, 37.83, 31.24, 29.58, 20.58, 20.52, 14.39; ESI-MS: *m/z* 591.7 [M+Na]<sup>+</sup>.

**4 $\beta$ -N-[(2'-(diethylamine)-acetamide)-4'-demethylpodophyllotoxin (12k)**

Yield 84% from **11** as a white solid; mp: 106–108 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.34 (s, 1H, OH-4'), 8.21 (d, *J* = 9.1 Hz, 1H, CONH), 6.96 (s, 1H, H-5), 6.80 (s, 1H, H-8), 6.45 (s, 2H, H-2', 6'), 6.02 (s, 2H, OCH<sub>2</sub>O), 5.13 (dd, *J* = 9.1, 6.2 Hz, 1H, H-4), 4.38 (s, 1H, H-1), 4.29 (m, 1H, 11 $\beta$ -H), 4.10 (m, 1H, 11 $\alpha$ -H), 3.81 (dd, *J* = 10.7, 2.2 Hz, 1H, H-2), 3.71 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.45 (m, 1H,

H-3), 3.15 (s, 2H, COCH<sub>2</sub>), 2.58 (q,  $J = 7.0$  Hz, 4H, CH<sub>2</sub>NCH<sub>2</sub>), 1.00 (t,  $J = 7.0$  Hz, 6H, 2 CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  179.08, 171.24, 148.36, 146.95, 146.87, 134.77, 131.72, 131.10, 129.48, 110.13, 105.99, 105.53, 101.51, 68.08, 56.51, 48.04, 46.35, 45.55, 43.99, 37.72, 19.03, 12.38; ESI-MS:  $m/z$  513.5 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2''-(diethanolamine)-acetamide)-4'-demethylpodophyllotoxin (12l)]**

Yield 71% from **11** as a white solid; mp: 212-214 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.29 (s, 1H, OH-4'), 8.26 (d,  $J = 8.6$  Hz, 1H, CONH), 6.77 (s, 1H, H-5), 6.53 (s, 1H, H-8), 6.25 (s, 2H, H-2', 6'), 6.01 (s, 2H, OCH<sub>2</sub>O), 5.20 (dd,  $J = 8.4, 4.8$  Hz, 1H, H-4), 4.53 (s, 2H, 2OH), 4.48 (d,  $J = 5.2$  Hz, 1H, H-1), 4.29 (m, 1H, 11 $\beta$ -H), 3.72 (m, 1H, 11 $\alpha$ -H), 3.64 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.41 (m, 4H, 2OCH<sub>2</sub>), 3.36 (s, 2H, COCH<sub>2</sub>), 3.24 (m, 1H, H-2), 2.95 (m, 1H, H-3), 2.59 (m, 4H, 2NCH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  175.04, 171.67, 147.63, 147.59, 147.02, 135.11, 132.79, 130.69, 130.64, 109.90, 109.33, 108.89, 101.68, 68.88, 59.26, 58.81, 57.85, 56.44, 46.98, 43.44, 41.21, 37.16; ESI-MS:  $m/z$  545.5 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2''-(diethanolamine)-acetamide)-podophyllotoxin (12m)]**

Yield 80% from **11** as a white solid; mp: 105-107 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.52 (d,  $J = 9.2$  Hz, 1H, CONH), 7.06 (s, 1H, H-5), 6.91 (s, 1H, H-8), 6.50 (s, 2H, H-2', 6'), 6.03 (s, 2H, OCH<sub>2</sub>O), 5.11 (dd,  $J = 9.0, 6.2$  Hz, 1H, H-4), 4.70 (s, 2H, 2OH), 4.30 (m, 1H, H-1), 4.07 (m, 1H, 11 $\beta$ -H), 3.86 (m, 1H, 11 $\alpha$ -H), 3.73 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.63 (s, 3H, 4'-OCH<sub>3</sub>), 3.49 (m, 4H, 2OCH<sub>2</sub>), 3.40 (m, 1H, H-2), 3.37 (s, 2H, COCH<sub>2</sub>), 3.18 (m, 1H, H-3), 2.65 (m, 4H, 2NCH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  179.08, 172.13, 153.20, 147.17, 146.81, 136.60, 136.51, 131.06, 129.57, 110.23, 106.09, 105.16, 101.46, 68.16, 60.44, 59.38, 59.18, 57.72, 56.31, 46.40, 46.09, 44.01, 37.43; ESI-MS:  $m/z$  559.6 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2''-(benzylamine)-acetamide)-4'-demethylpodophyllotoxin (12n)]**

Yield 85% from **11** as a white solid; mp: 141-143 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.31 (s, 1H, OH-4'), 8.22 (d,  $J = 8.3$  Hz, 1H, CONH), 7.33 (s, 2H, 3'',5''-ArH), 7.32 (d,  $J = 1.4$  Hz, 2H, 2'',6''-ArH), 7.25 (m, 1H, 4''-ArH), 6.81 (s, 1H, H-5), 6.55 (s, 1H, H-8), 6.25 (s, 2H, H-2', 6'), 6.02 and 6.01 (2s, 2H, OCH<sub>2</sub>O), 5.21 (dd,  $J = 8.3, 4.7$  Hz, 1H, H-4), 4.50 (d,  $J = 5.1$  Hz, 1H, H-1), 4.29 (m, 1H, 11 $\beta$ -H), 3.76 (m, 1H, 11 $\alpha$ -H), 3.73 (s, 2H, Ar-CH<sub>2</sub>), 3.71 (s, 1H, NH), 3.64 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.22 (s, 2H, COCH<sub>2</sub>), 3.17 (dd,  $J = 10.6, 3.8$  Hz, 1H, H-2), 2.96 (m, 1H, H-3); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  174.98, 171.11, 147.70, 147.60, 147.04, 139.93, 135.12, 132.79, 130.64, 130.59, 128.76, 128.67, 127.41, 109.91, 109.48, 108.86, 101.73, 68.83, 56.43, 52.82, 51.31, 47.15, 43.36, 41.32, 37.04; ESI-MS:  $m/z$  547.6 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2''-(benzylamine)-acetamide)-podophyllotoxin (12o)]**

Yield 88% from **11** as a white solid; mp: 111-113 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.31 (d,  $J = 8.3$  Hz, 1H, CONH), 7.34 (2, 2H, 3'',5''-ArH), 7.32 (m, 2H, 2'',6''-ArH), 7.28 (m, 1H, 4''-ArH), 6.81 (s, 1H, H-5), 6.55 (s, 1H, H-8), 6.30 (s, 2H, H-2', 6'), 6.02 and 6.01 (2s, 2H, OCH<sub>2</sub>O), 5.22 (dd,  $J = 8.1, 4.6$  Hz, 1H,

H-4), 4.55 (d,  $J = 5.2$  Hz, 1H, H-1), 4.30 (m, 1H, 11 $\beta$ -H), 3.79 (s, 2H, Ar-CH<sub>2</sub>), 3.76 (s, 1H, NH), 3.73 (m, 1H, 11 $\alpha$ -H), 3.66 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.62 (s, 3H, 4'-OCH<sub>3</sub>), 3.28 (s, 2H, COCH<sub>2</sub>), 3.21 (dd,  $J = 14.5, 5.4$  Hz, H-2), 2.97 (m, 1H, H-3); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  174.89, 172.51, 152.46, 147.76, 147.13, 136.78, 136.23, 132.40, 130.62, 129.00, 128.73, 127.68, 109.89, 109.56, 108.56, 101.77, 68.85, 60.35, 56.21, 52.51, 50.80, 47.16, 43.53, 41.14, 37.07; ESI-MS:  $m/z$  561.6 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2''-(4-fluoroaniline)-acetamide)-4'-demethylpodophyllotoxin (12p)]**

Yield 88% from **11** as a white solid; mp: 159-162 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.34 (d,  $J = 8.3$  Hz, 1H, CO NH), 8.28 (s, 1H, OH-4'), 6.92 (t,  $J = 9.0$  Hz, 2H, ArH-3'', 5''), 6.69 (s, 1H, H-5), 6.56 (dd,  $J = 9.0, 4.5$  Hz, 2H, ArH-2'', 6''), 6.54 (s, 1H, H-8), 6.24 (s, 2H, H-2', 6'), 6.01 and 5.99 (2s, 2H, OCH<sub>2</sub>O), 5.86 (m, 1H, H-1), 5.20 (dd,  $J = 8.3, 4.7$  Hz, 1H, H-4), 4.49 (d,  $J = 5.2$  Hz, 1H, 11 $\beta$ -H), 4.23 (m, 1H, 11 $\alpha$ -H), 3.72 (d,  $J = 5.9$  Hz, 1H, NH), 3.63 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.36 (s, 2H, COCH<sub>2</sub>), 3.17 (dd,  $J = 14.4, 5.2$  Hz, 1H, H-2), 3.00-2.85 (m, 1H, H-3); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  174.95, 170.81, 156.26, 153.96, 147.67, 147.60, 147.00, 145.44, 135.12, 132.75, 130.67, 130.57, 115.74, 115.52, 113.73, 113.66, 109.86, 109.43, 108.87, 101.69, 68.74, 56.43, 47.56, 47.22, 43.38, 41.25, 36.98; ESI-MS:  $m/z$  573.5 [M+Na]<sup>+</sup>.

**4 $\beta$ -N-[(2''-(3,4-dimethoxyphenethylamine)-acetamide)-4'-demethylpodophyllotoxin (12q)]**

Yield 85% from **11** as a white solid; mp: 229-231 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.60 (d,  $J = 8.2$  Hz, 1H, CONH), 7.95 (s, 1H, OH-4'), 6.84 (d,  $J = 8.2$  Hz, 1H, 5''-ArH), 6.82 (d,  $J = 1.7$  Hz, 1H, 2''-ArH), 6.78 (s, 1H, H-5), 6.72 (dd,  $J = 8.2, 1.7$  Hz, 1H, 6''-ArH), 6.53 (s, 1H, H-8), 6.25 (s, 2H, H-2', 6'), 6.01 and 5.99 (2s, 2H, OCH<sub>2</sub>O), 5.22 (dd,  $J = 8.2, 4.5$  Hz, 1H, H-4), 4.50 (d,  $J = 5.1$  Hz, 1H, H-1), 4.28 (m, 1H, 11 $\beta$ -H), 3.83 (m, 1H, 11 $\alpha$ -H), 3.71 (s, 1H, NH), 3.74 (s, 6H, 3'',4''-OCH<sub>3</sub>), 3.65 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.53 (d,  $J = 3.9$  Hz, 1H, H-3), 3.12 (dd,  $J = 14.4, 5.2$  Hz, 1H, H-2), 2.96 (m, 2H, NCH<sub>2</sub>), 2.90 (s, 2H, COCH<sub>2</sub>), 2.78 (t,  $J = 7.5$  Hz, 2H, Ar-CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  174.79, 172.47, 162.70, 149.12, 147.82, 147.80, 147.59, 147.07, 135.14, 132.74, 131.36, 130.46, 130.25, 120.89, 112.83, 112.23, 108.84, 101.73, 79.75, 79.42, 79.09, 56.40, 55.91, 55.80, 49.88, 47.32, 43.36, 36.26, 31.22, 21.52; ESI-MS:  $m/z$  643.6 [M+Na]<sup>+</sup>.

**4 $\beta$ -N-[(2''-(3,4-dimethoxyphenethylamine)-acetamide)-podophyllotoxin (12r)]**

Yield 85% from **11** as a white solid; mp: 106-108 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.75 (d,  $J = 8.1$  Hz, 1H, CONH), 6.78 (d, 1H, H-5), 6.75-6.67 (m, 3H, Ar-H), 6.53 (s, 1H, H-8), 6.27 (s, 2H, H-2', 6'), 5.97 (s, 2H, OCH<sub>2</sub>O), 5.21 (dd,  $J = 8.1, 4.7$  Hz, 1H, H-4), 4.54 (d,  $J = 5.1$  Hz, 1H, H-1), 4.40-4.31 (m, 1H, 11 $\beta$ -H), 4.13 (m, 1H, 11 $\alpha$ -H), 4.10 (s, 1H, NH), 3.92 (s, 3H, 4'-OCH<sub>3</sub>), 3.81 (s, 3H, Ar-OCH<sub>3</sub>), 3.78 (s, 3H, Ar-OCH<sub>3</sub>), 3.75 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.45 (d, 1H, H-3), 3.08-3.00 (m, 1H, H-2), 2.89 (s, 2H, COCH<sub>2</sub>), 2.84-2.70 (m, 2H, NCH<sub>2</sub>), 2.65 (m, 1H, Ar-CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  175.79, 174.44, 169.91, 152.58, 148.94, 148.22, 147.73, 147.45, 137.16, 134.93, 132.35, 130.84, 128.69, 120.70,

111.78, 111.35, 110.27, 108.84, 108.16, 101.56, 68.76, 60.77, 56.20, 55.83, 55.76, 51.11, 50.98, 47.57, 43.60, 41.54, 37.03, 34.73, 20.98; ESI-MS:  $m/z$  635.7 [M+H]<sup>+</sup>.

**4 $\beta$ -N-[(2'-(4-hydroxyphenylethylamine)-acetamide)-4'-demethylpodophyllotoxin (12s)**

Yield 89% from **11** as a white solid; mp: 234–236 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  9.33 (s, 1H, OH-4'), 8.73 (d,  $J$  = 8.2 Hz, 1H, CONH), 8.30 (s, 1H, OH-4'), 7.00 (d,  $J$  = 8.4 Hz, 2H, ArH-2'', 6''), 6.79 (s, 1H, H-5), 6.70 (d,  $J$  = 8.4 Hz, 2H, ArH-3'', 5''), 6.55 (s, 1H, H-8), 6.25 (s, 2H, H-2', 6'), 6.02 and 6.00 (2s, 2H, OCH<sub>2</sub>O), 5.22 (dd,  $J$  = 8.2, 4.5 Hz, 1H, H-4), 4.52 (d,  $J$  = 5.1 Hz, 1H, H-1), 4.29 (m, 1H, 11 $\beta$ -H), 4.07–3.78 (m, 1H, 11 $\alpha$ -H), 3.64 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.59 (s, 2H, COCH<sub>2</sub>), 3.19 (dd,  $J$  = 14.4, 5.2 Hz, 1H, H-2), 3.00 (m, 1H, H-3), 2.94 (t, 2H, NCH<sub>2</sub>), 2.75 (t, 2H, CH<sub>2</sub>-Ar), 1.92 (s, 1H, NH); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  174.89, 156.43, 147.77, 147.61, 147.02, 135.13, 132.80, 130.54, 130.29, 129.95, 128.57, 115.75, 109.97, 109.47, 108.86, 101.76, 68.71, 56.43, 49.73, 49.55, 47.37, 43.31, 41.38, 36.94, 32.64; ESI-MS:  $m/z$  599.6 [M+Na]<sup>+</sup>.

**4 $\beta$ -N-[2'-(4-hydroxyphenylethylamine)-acetamide]-podophyllotoxin (12t)**

Yield 81% from **11** as a white solid; mp: 116–119 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.01 (s, 1H, Ar-OH), 7.80 (d,  $J$  = 9.0 Hz, 1H, CONH), 6.99 (d,  $J$  = 8.3 Hz, 2H, Ar-H), 6.71 (d,  $J$  = 8.3 Hz, 2H, Ar-H), 6.67 (s, 1H, H-5), 6.63 (s, 1H, H-8), 6.36 (s, 2H, H-2', 6'), 5.97 and 5.96 (2s, 2H, OCH<sub>2</sub>O), 5.30 (dd,  $J$  = 9.1, 5.1 Hz, 1H, H-4), 4.43 (d, 1H, H-1), 4.20 (m, 1H, 11 $\beta$ -H), 4.14 (m, 1H, 11 $\alpha$ -H), 3.82 (s, 3H, 4'-OCH<sub>3</sub>), 3.79 (s, 6H, 3',5'-OCH<sub>3</sub>), 3.44 (dd,  $J$  = 10.3, 2.8 Hz, 1H, H-2), 3.36 (d, 2H, COCH<sub>2</sub>), 3.24 (m, 1H, H-3), 2.93 (s, 1H, NH), 2.86 (d,  $J$  = 4.0 Hz, 2H, NCH<sub>2</sub>), 2.70 (t,  $J$  = 7.1 Hz, 2H, CH<sub>2</sub>-Ar); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>):  $\delta$  179.01, 171.69, 155.06, 153.47, 147.62, 147.43, 137.37, 136.84, 130.23, 130.16, 129.77, 128.22, 116.26, 116.18, 115.80, 115.60, 115.57, 110.02, 106.08, 104.79, 101.41, 68.51, 60.87, 56.22, 51.56, 51.35, 47.30, 45.41, 45.31, 37.88, 34.97, 29.71, 14.20; ESI-MS:  $m/z$  591.6 [M+H]<sup>+</sup>.

## Biological Evaluation

### Cell Culture

The four human cancer cell lines and a normal human epidermal cell line of the screening panel, including H460 (human non-small cell lung carcinoma), HeLA (human cervical carcinoma), EC9706 (human esophageal squamous cell carcinoma), T24 (human bladder carcinoma), and HaCaT (human immortalized epidermal cells), were purchased from American Type Culture Collection (ATCC, Manassas, VA, U.S.A.). H460, EC9706, and T24 were maintained in RPMI 1640 medium containing 10% Fetal Bovine Serum, 100 units/ml penicillin, 100  $\mu$ g/ml streptomycin under humidified incubator with 5% CO<sub>2</sub> atmosphere at 37°C. HeLA and HaCaT were maintained in Dulbecco's Minimum Essential Medium (DMEM) supplemented with 10% Fetal Bovine Serum 100 units/ml penicillin, 100  $\mu$ g/ml streptomycin in a humidified incubator and 5% CO<sub>2</sub> atmosphere at 37°C. Logarithmically growing cells were used for the following experiments.

### Antiproliferative Assay

The cytotoxicity of the synthesized compounds **12a–t** against a panel of human cell lines was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) growth inhibition assay. The five human cell lines were, respectively, plated in 96-well-culture plates at the density of  $1 \times 10^5$  cells per well and incubated for 24 h. Cells were exposed to different concentrations of synthetic podophyllotoxin derivatives for 48 h. MTT was added with a dose of 5 mg/mL in phosphate-buffered saline. After incubation for 4 h at 37°C, the purple formazan crystals were dissolved with 100 mL dimethyl sulfoxide and the absorbance was measured at 570 nm in an ELISA reader. Antiproliferative activity was expressed using the IC<sub>50</sub> value defined as the concentration of synthetic podophyllotoxin derivatives inhibiting cell proliferation by 50%. The cell viability ratio was calculated by the following formula: cell viability ratio (%) = OD treated / OD control  $\times$  100% (Ma et al., 2014).

### Hoechst 33258 Staining

T24 and HeLA cells were seeded at a density of  $3 \times 10^4$  cells per well and cultured in 6 well-plates on a cover slip for 24 h at 37°C. Compound **12g** treated T24 and HeLA cancer cells for 24 h at 37°C with concentrations of 0.5/1.0/2.0 and 0.75/1.5/3.0  $\mu$ M, respectively. Afterward, the treated cells were fixed with 4% paraformaldehyde (PFA) for 30 min and stained with 5  $\mu$ g/mL Hoechst 33258 (bis-benzimide; KeyGEN Bio TECH, China) for 30 min. Nuclei were stained with Hoechst 33258 to examine chromatin condensation or nuclear fragmentation, morphological characteristics of apoptosis. After the cells were washed twice with PBS, the cover slip was inverted and placed on a glass slide and mounted. Apoptotic cells with fluorescence of the soluble DNA fragments were detected directly and photographed under a phase contrast microscope (OLYMPUS IX51, Japan) in a Varian Fluorometer at an excitation wavelength of 365 nm and emission wavelength of 460 nm (Shareef et al., 2015).

### Cell Cycle Distribution Analysis

To understand the cell cycle effect of the synthesized analogs, cell cycle distribution analysis was performed by FACS (Becton Dickinson, San Jose, CA, USA). T24 and HeLA cells were treated with compound **12g** for 24 h at 37°C with concentrations of 0.5/1.0/2.0 and 0.75/1.5/3.0  $\mu$ M, respectively. After treatment, the cells were washed once with PBS and fixed with 70% ice-cold ethanol at 20°C for overnight. Ethanol was removed by Centrifugation. The cells were stained with a solution containing 0.1% Triton-X 100 (Sigma), 0.2 mg/mL RNase (Sigma), and 20 mg/mL propidium iodide (PI, Sigma) in the dark for 30 min at room temperature. Then, cell cycle distribution was analyzed by using a FACS can flow cytometer (Chen et al., 2013).

### Molecular Docking Study

Docking study simulations were performed using AutoDock 4.0 to investigate the potential binding mode of the synthesized compound **12g** in the active site of human DNA topoisomerase II $\alpha$  (PDB: 1ZXN, Available from: <https://www.rcsb.org/>

structure/1ZXM) and to predict its mechanism of action as an anti-cancer agent. Autogrid was employed using a grid box volume of  $50 \times 50 \times 50 \text{ \AA}$  centered on the active site of human DNA topoisomerase II $\alpha$ . The 3D structures of the synthesized compounds were employed to achieve the docking study (Chen et al., 2013; Shareef et al., 2015). The docking protocol was then applied and 100 poses per compound were generated, and the best docked structure was chosen to fulfill the docking procedure. The docking protocol mainly consisted of four steps. (1) Ligand preparation: Chemdraw 11.0 was employed to process the structure of small molecule **12g**; after energy minimization optimization, the small molecule was saved in the mol2 format, which was then converted into a pdbqt file by Autodock 4.0. (2) Receptor preparation: after removal of water molecules, its natural ligand and excess protein chains in the structure of 1ZXM downloaded from the pdb database, the protein 1ZXM was processed with Autodock 4.0. via hydrogenation, calculation of charge, and combination of non-polar hydrogen, which was saved as pdbqt file. (3) Autogrid processing: the pdbqt file of protein 1ZXM was processed by autogrid to construct a  $50 \times 50 \times 50$  box centered on the active site of the protein, which generated a glg file. (4) Autodock operation: using the default software parameters, the small

molecule was autodocked with the protein in flexible docking, and the operation was processed 100 times to generate a dlq file. The final figures of the molecular modeling were visualized using PYMOL.

## AUTHOR CONTRIBUTIONS

JW was responsible for the experimental implementation and paper writing. JC, PJ, LM, LC, WM, and TZ provided literature retrieval and guidance for methods. GY was responsible for the coordination of this study. Y-XW was responsible for the paper editing.

## FUNDING

This work was supported financially by Taihe Hospital (2016JXXM090 and 2017JXXM034).

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fchem.2019.00253/full#supplementary-material>

## REFERENCES

- Canel, C., Moraes, R. M., Dayan, F. E., and Ferreira, D. (2000). Podophyllotoxin. *Phytochemistry* 54, 115–120. doi: 10.1016/S0031-9422(00)00094-7
- Chen, Y. F., Lin, Y. C., Huang, P. K., Chan, H. C., Kuo, S. C., Lee, K. H., et al. (2013). Design and synthesis of 6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-one derivatives as novel anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase. *Bioorg. Med. Chem.* 21, 5064–5075. doi: 10.1016/j.bmc.2013.06.046
- Cragg, G. M., and Newman, D. J. (2013). Natural products: a continuing source of novel drug leads. *Biochim. Biophys. Acta* 1830, 3670–3695. doi: 10.1016/j.bbagen.2013.02.008
- Damayanthi, Y., and Lown, J. W. (1998). Podophyllotoxins: current status and recent developments. *Curr. Med. Chem.* 5, 205–252.
- Gordaliza, M., Castro, M. A., del Corral, J. M., and Feliciano, A. S. (2000). Antitumor properties of podophyllotoxin and related compounds. *Curr. Pharm. Des.* 6, 1811–1839. doi: 10.2174/1381612003398582
- Gordaliza, M., Garcia, P. A., del Corral, J. M. M., Castro, M. A., and Gomez-Zurita, M. A. (2004). Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. *Toxicol.* 44, 441–459. doi: 10.1016/j.toxicol.2004.05.008
- Greco, F. A., and Hainsworth, J. D. (1996). Clinical studies with etoposide phosphate. *Sem. Oncol.* 23(6 Suppl. 13):45–50.
- Hande, K. R. (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. *Eur. J. Cancer* 34, 1514–1521.
- Hartley, R. M., Peng, J., Fest, G. A., Dakshanamurthy, S., Frantz, D. E., Brown, M. L., et al. (2012). Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site. *Mol. Pharmacol.* 81, 431–439. doi: 10.1124/mol.111.075838
- Hyder, I., Yedlapudi, D., Kalivendi, S. V., Khazir, J., Ismail, T., Nalla, N., et al. (2015). Synthesis and biological evaluation of novel 4 beta- (5-substituted)-1,2,3,4-tetrazolyl podophyllotoxins as anticancer compounds. *Bioorg. Med. Chem. Lett.* 25, 2860–2863. doi: 10.1016/j.bmcl.2015.04.053
- Issell, B. F. (1982). The podophyllotoxin derivatives VP16-213 and VM26. *Cancer Chemother. Pharmacol.* 7, 73–80. doi: 10.1007/BF00254525
- Jemal, A. (2011). Global cancer statistics (vol 61, pg 69, 2011). *CA Cancer J. Clin.* 61, 134–134. doi: 10.3322/caac.20107
- Kamal, A., Ali Hussaini, S. M., Rahim, A., and Riyaz, S. (2015). Podophyllotoxin derivatives: a patent review (2012 - 2014). *Expert Opin. Ther. Pat.* 25, 1025–1034. doi: 10.1517/13543776.2015.1051727
- Keller-Juslen, C., Kuhn, M., Stahelin, H., and von Wartburg, A. (1971). Synthesis and antimetabolic activity of glycosidic lignan derivatives related to podophyllotoxin. *J. Med. Chem.* 14, 936–940. doi: 10.1021/jm00292a012
- Khazir, J., Riley, D. L., Pilcher, L. A., De-Maayer, P., and Mir, B. A. (2014). Anticancer agents from diverse natural sources. *Nat. Prod. Commun.* 9, 1655–1669. doi: 10.1177/1934578X1400901130
- Komericki, P., Akkilic-Materna, M., Strimitzer, T., and Aberer, W. (2011). Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. *Sex. Transm. Dis.* 38, 216–218. doi: 10.1097/OLQ.0b013e3181f68ebb
- Lear, Y., and Durst, T. (1996). Synthesis and biological evaluation of carbon-substituted C-4 derivatives of podophyllotoxin. *Can. J. Chem.* 74, 1704–1708. doi: 10.1139/v96-187
- Li, W. Q., Wang, X. L., Qian, K., Liu, Y. Q., Wang, C. Y., Yang, L., et al. (2013). Design, synthesis and potent cytotoxic activity of novel podophyllotoxin derivatives. *Bioorg. Med. Chem.* 21, 2363–2369. doi: 10.1016/j.bmc.2013.01.069
- Liu, Y. Q., Tian, J., Qian, K., Zhao, X. B., Morris-Natschke, S. L., Yang, L., et al. (2015). Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents. *Med. Res. Rev.* 35, 1–62. doi: 10.1002/med.21319
- Loike, J. D. (1982). VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity. *Cancer Chemother. Pharmacol.* 7, 103–111.
- Lopez-Lopez, D., Agrasar-Cruz, C., Bautista-Casasnovas, A., and Alvarez-Castro, C. J. (2015). Application of cantharidin-podophyllotoxin-salicylic acid in recalcitrant plantar warts. A preliminary study. *Gac. Med. Mex.* 151, 14–19.
- Lv, M., and Xu, H. (2011). Recent advances in semisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: an update (2008–2010). *Mini Rev. Med. Chem.* 11, 901–909. doi: 10.2174/138955711796575461
- Ma, W. D., Zou, Y. P., Wang, P., Yao, X. H., Sun, Y., Duan, M. H., et al. (2014). Chimaphilin induces apoptosis in human breast cancer MCF-7 cells through a ROS-mediated mitochondrial pathway. *Food Chem. Toxicol.* 70, 1–8. doi: 10.1016/j.fct.2014.04.014

- MacRae, W. D., Hudson, J. B., and Towers, G. H. (1989). The antiviral action of lignans. *Planta Med.* 55, 531–535. doi: 10.1055/s-2006-962087
- Moon, J. Y., Baek, S. W., Ryu, H., Choi, Y. S., Song, I. C., Yun, H. J., et al. (2017). VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. *Medicine* 96:e5942. doi: 10.1097/MD.0000000000005942
- Nandagopal, K., and Routh, S. (2017). Patent survey of resveratrol, taxol, podophyllotoxin, withanolides and their derivatives used in anticancer therapy. *Recent Pat. Biotechnol.* 11, 85–100. doi: 10.2174/1872208311666170127114804
- Newman, D. J., and Cragg, G. M. (2016). Natural products as sources of new drugs from 1981 to 2014. *J. Nat. Prod.* 79, 629–661. doi: 10.1021/acs.jnatprod.5b01055
- Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., et al. (2004). Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. *Nature* 428, 198–202. doi: 10.1038/nature02393
- Shareef, M. A., Duscharla, D., Ramasatyaveni, G., Dhoke, N. R., Das, A., Ummanni, R., et al. (2015). Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties. *Eur. J. Med. Chem.* 89:128–137. doi: 10.1016/j.ejmech.2014.10.050
- Shimizu, K., Takada, M., Asai, T., Irimura, K., Baba, K., and Oku, N. (2002). Potential usage of liposomal 4 $\beta$ -aminoalkyl-4'-O-demethyl-4-desoxy-podophyllotoxin (TOP-53) for cancer chemotherapy. *Biol. Pharm. Bull.* 25, 783–786. doi: 10.1248/bpb.25.783
- Srivastava, V., Negi, A. S., Kumar, J. K., Gupta, M. M., and Khanuja, S. P. (2005). Plant-based anticancer molecules: a chemical and biological profile of some important leads. *Bioorg. Med. Chem.* 13, 5892–5908. doi: 10.1016/j.bmc.2005.05.066
- Utsugi, T., Shibata, J., Sugimoto, Y., Aoyagi, K., Wierzba, K., Kobunai, T., et al. (1996). Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. *Cancer Res.* 56, 2809–2814.
- Wilstermann, A. M., Bender, R. P., Godfrey, M., Choi, S., Anklin, C., Berkowitz, D. B., et al. (2007). Topoisomerase II-drug interaction domains: identification of substituents on etoposide that interact with the enzyme. *Biochemistry* 46, 8217–8225. doi: 10.1021/bi700272u
- Witterland, A. H., Koks, C. H., and Beijnen, J. H. (1996). Etoposide phosphate, the water soluble prodrug of etoposide. *Pharm. World Sci.* 18, 163–170. doi: 10.1007/BF00820727
- You, Y. J. (2005). Podophyllotoxin derivatives: Current synthetic approaches for new anticancer agents. *Curr. Pharm. Des.* 11, 1695–1717. doi: 10.2174/1381612053764724
- Yu, X., Che, Z., and Xu, H. (2017). Recent advances in the chemistry and biology of podophyllotoxins. *Chemistry* 23, 4467–4526. doi: 10.1002/chem.201602472
- Zhang, J. Q., Zhang, Z. W., Hui, L., Chen, S. W., and Tian, X. (2010). Novel semisynthetic spin-labeled derivatives of podophyllotoxin with cytotoxic and antioxidative activity. *Bioorg. Med. Chem. Lett.* 20, 983–986. doi: 10.1016/j.bmcl.2009.12.048

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Wei, Chen, Ju, Ma, Chen, Ma, Zheng, Yang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.